Search results: Sage Journals

Restricted accessResearch articleFirst published April, 2003

Additional Radiation Absorbed Dose Estimates for Zevalin™ Radioimmunotherapy

Gregory A. Wiseman, Bryan R. Leigh, William L. Dunn [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2003

Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

Gregory A. Wiseman, Bryan R. Leigh, William D. Erwin [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2005

Testicular Uptake and Radiation Dose in Patients Receiving Zevalin ™ and Pretarget ™ CC49Fusion Protein

Sui Shen, Ruby Meredith, Jun Duan [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2005

Yttrium-90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) Induces Long-Term Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Gregory A. Wiseman, Thomas E. Witzig

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2006

Case Report : Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin ® ): A Case Report

Gethin Williams, Matthew R. Palmer, J. Anthony Parker [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2007

Imaging of the Distribution of 90 Y-Ibritumomab Tiuxetan in Bone Marrow and Comparison with Pathology

Jeremy Coulot, Valérie Camara-Clayette, Marcel Ricard [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2007

Dosimetry in Myeloablative 90 Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results

Carlo Chiesa, Francesca Botta, Erika Di Betta [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2007

Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma

Christos Emmanouilides, Thomas E. Witzig, Gregory A. Wiseman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published March, 2013

Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving 90 Y-Ibritumomab-Tiuxetan

Francesco Cicone, Marco D'Arienzo, Andrea Carpaneto [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published December, 2006

Update : Renaissance of Targeting Molecules for Melanoma

Ekaterina Dadachova, Arturo Casadevall

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2003

Additional Radiation Absorbed Dose Estimates for Zevalin™ Radioimmunotherapy

Gregory A. Wiseman, Bryan R. Leigh, William L. Dunn [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2003

Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalin™) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia

Gregory A. Wiseman, Bryan R. Leigh, William D. Erwin [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2005

Testicular Uptake and Radiation Dose in Patients Receiving Zevalin ™ and Pretarget ™ CC49Fusion Protein

Sui Shen, Ruby Meredith, Jun Duan [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2005

Yttrium-90 ( 90 Y) Ibritumomab Tiuxetan (Zevalin ® ) Induces Long-Term Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Gregory A. Wiseman, Thomas E. Witzig

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published April, 2006

Case Report : Extravazation of Therapeutic Yttrium-90-Ibritumomab Tiuxetan (Zevalin ® ): A Case Report

Gethin Williams, Matthew R. Palmer, J. Anthony Parker [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2007

Imaging of the Distribution of 90 Y-Ibritumomab Tiuxetan in Bone Marrow and Comparison with Pathology

Jeremy Coulot, Valérie Camara-Clayette, Marcel Ricard [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2007

Dosimetry in Myeloablative 90 Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results

Carlo Chiesa, Francesca Botta, Erika Di Betta [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published October, 2007

Safety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma

Christos Emmanouilides, Thomas E. Witzig, Gregory A. Wiseman [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published March, 2013

Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving 90 Y-Ibritumomab-Tiuxetan

Francesco Cicone, Marco D'Arienzo, Andrea Carpaneto [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published December, 2006

Update : Renaissance of Targeting Molecules for Melanoma

Ekaterina Dadachova, Arturo Casadevall

Cancer Biotherapy and Radiopharmaceuticals